To make headroom for expensive, potentially curative therapies in the pipeline, the healthcare needs to remove ineffective care from the system, said Susan Dentzer, visiting fellow at the Duke-Margolis Center for Health Policy.
To make headroom for expensive, potentially curative therapies in the pipeline, the healthcare needs to remove ineffective care from the system, said Susan Dentzer, visiting fellow at the Duke-Margolis Center for Health Policy.
Transcript
How do we balance the desire for innovation with the rising costs of healthcare delivery, particularly in cancer care?
We balance it awkwardly to be frank. We have at least a thousand innovative cancer drugs in the pipeline today, which will be coming to the market over the next several years. Many of them will be life-changing therapies. They will essentially, but not necessarily, be cures, but they really will be disease-modifying therapies. People are going to want them. And we’re going to want to integrate them into our health system.
The issue, I think, on balance is how much of care that we are currently undertaking that is not all that effective can we displace? Therefore, if we bring on board therapies that are even more effective, are we at least achieving higher value even if the costs go up? That, alone, would be a positive. But, let’s face it: We have all kinds of forces that are going to drive us to higher and higher rates of healthcare spending and what is going to happen in cancer, I’m sure, is one of them.
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Patients With Advanced, Recurrent Melanoma May Experience Lasting AEs From ICM Therapy
May 9th 2024A cross-sectional, mixed-methods study found that adverse effects (AEs) can occur even after 1 year of treatment with immune checkpoint modulator (ICM) therapy in patients with melanoma.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen